863031-24-7
- Product Name：Azilsartan Medoxomil Potassium
- Molecular Formula：C30H24N4O8.K
- Purity：99%
- Molecular Weight：607.63200
Product Details:
CasNo： 863031-24-7
Molecular Formula： C30H24N4O8.K
Appearance： White or offwhite powder
Buy Quality Azilsartan Medoxomil Potassium,99% Pure 863031-24-7 Efficient Delivery
- Molecular Formula:C30H24N4O8.K
- Molecular Weight:607.63200
- Appearance/Colour:White or offwhite powder
- PSA：152.69000
- LogP:4.33430
Azilsartan kaMedoxoMil(Cas 863031-24-7) Usage
|
Description |
Developed by Takeda Pharmaceuticals, azilsartan medoxomil potassium was approved for hypertension treatment and launched in the U.S. as Edarbi. It can be used as monotherapy or in combination with other antihypertensive agents. Clinical studies have shown that it demonstrates superior antihypertensive activity and a favorable safety profile compared to other established therapeutics. |
|
Uses |
Azilsartan Medoxomil Potassium is a prodrug primarily used to treat hypertension in adults aged 18 and older. Marketed under the brand name Edarbi, it can be used alone or in combination with other antihypertensive drugs. The medication has minimal impact on serum potassium or sodium levels. Azilsartan medoxomil potassium tablets are available in various strengths, including 20 mg, 40 mg, or 80 mg of azilsartan medoxomil (as potassium). It is typically administered once daily, with or without food. |
|
Clinical Use |
The chemical structure of azilsartan medoxomil potassium, the monopotassium salt of azilsartan medoxomil, is responsible for its therapeutic effects. Azilsartan medoxomil is a prodrug that is metabolized to azilsartan, which acts as an angiotensin receptor antagonist. By blocking the action of angiotensin II, azilsartan helps to relax blood vessels, making it easier for blood to flow and thereby reducing high blood pressure. |
InChI:InChI:1S/C30H24N4O8.K/c1-3-38-28-31-23-10-6-9-22(27(35)39-16-24-17(2)40-30(37)41-24)25(23)34(28)15-18-11-13-19(14-12-18)20-7-4-5-8-21(20)26-32-29(36)42-33-26;/h4-14H,3,15-16H2,1-2H3,(H,32,33,36);/q;+1/p-1
863031-24-7 Relevant articles
Azilsartan Medoxomil (Edarbi) The Eighth Angiotensin II Receptor Blocker
Jocelyn D. Jones, PharmD, BCPS, Sylvia H. Jackson, PharmD, MEd, CDE, Carmen Agboton, PharmD, and Tonya S. Martin, PharmD, CGP, MAEd
, P T. 2011 Oct; 36(10): 634-636, 638-640.
This salt is practically insoluble in water and is freely soluble in methanol. Each white, round, unscored tablet of azilsartan medoxomil contains 42.68 mg or 85.36 mg of the potassium salt, which is equivalent to 40 mg and 80 mg of azilsartan medoxomil, respectively.
Liquid chromatography/tandem mass spectrometry study of forced degradation of azilsartan medoxomil potassium
Debasish Swain, Prinesh N. Patel, Ilayaraja Palaniappan, Gayatri Sahu, Gananadhamu Samanthula
Rapid Communications in Mass Spectrometry, Volume29, Issue15 15 August 2015 Pages 1437-1447
Azilsartan medoxomil potassium (AZM) is a new antihypertensive drug introduced in the year 2011. The presence of degradation products not only affects the quality, but also the safety aspects of the drug. Thus, it is essential to develop an efficient analytical method which could be useful to selectively separate and identify the degradation products of azilsartan medoxomil potassium.
Relevant Products
-
Levofloxacin HemihydrateCAS：138199-71-0
-
RiociguatCAS：625115-55-1
-
TopiroxostatCAS：577778-58-6
